Amid growing interest from med tech companies in innovative bionic devices, an Icelandic orthopedics company is developing tiny implanted myoelectric sensors that allow patients to control prosthetic limbs with their minds.
A couple of years back--before Orexigen's recent data leak landed it in hot water with regulators, researchers and marketing partner Takeda--CEO Mike Narachi said he believed data from a large cardiovascular outcomes study should be kept among "a small team." But he also believed he should be on that team.
Royal Philips and the Massachusetts Institute of Technology (MIT) have partnered in a 5-year research alliance with a $25 million budget to develop novel product solutions in healthcare and lighting.
MIT and Harvard's collaborative Broad Institute just received a $10 million gift from the Gerstner Family Foundation to conduct research into drug-resistant cancers using gene-editing technology and blood-based tumor biopsies.
Veracyte has been generating cash for R&D and striking deals to expand its market reach. Now, the company is touting promising results for its bronchial genomic classifier for lung cancer diagnosis as it takes a deeper dive into the lung cancer testing market.
UCSD researchers have developed a hydrogel that contains toxin-absorbing nanoparticles--what they are calling nanosponges--that could eventually treat skin and wound conditions caused by methicillin-resistant Staphylococcus aureus, or MRSA.
Endo Pharmaceuticals and BioDelivery Sciences International announced positive results from two Phase III studies of their Belbuca buccal film to manage severe chronic pain by quickly delivering buprenorphine via the inside of the cheek. The candidate uses BDSI's BioErodible MucoAdhesive delivery platform.
PatientsLikeMe has lured Jason Johnson away from Merck. Johnson is leaving Merck after 14 years at the Big Pharma to head up R&D at PatientsLikeMe, a role which gives him responsibility for efforts to extract insights from patient-reported data.
Israel has become the latest country to disclose plans to create a population-scale database of linked genetic and clinical records. The current plan is reminiscent of the United Kingdom's 100,000 Genomes Project, with Israel considering working with tech firms to create a database of patients with rare genetic diseases.
Sorrento Therapeutics, a frequent partner of billionaire biotech entrepreneur Patrick Soon-Shiong, launched a new subsidiary to advance its take on CAR-T therapies for cancer, taking a page from its patron as it tosses more and more irons in the R&D fire.